© 2021 MJH Life Sciences and AJMC. All rights reserved.
© 2021 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
June 15, 2021
On this episode of Managed Care Cast, we speak with the author of the annual PwC Behind the Numbers report, which looks ahead at medical cost trends in the United States.
Dapagliflozin substantially slowed the progression of chronic kidney disease (CKD) in patients with immunoglobulin A nephropathy, according to a new study.
Michael Thorpy, MD, director, Sleep-Wake Disorders Center, Montefiore Medical Center, and professor of neurology, Albert Einstein College of Medicine, speaks on the efficacy of solriamfetol observed in patients with excessive daytime sleepiness associated with narcolepsy, and which patient groups may best benefit from this therapy.
Findings from a retrospective cohort study revealed that individuals with osteoarthritis are more susceptible to the development of Parkinson disease.
A recent decline in the proportion of adults with diabetes achieving glycemic control may contribute to more diabetes-related health issues and deaths across America.
The debate continues whether or not to go maskless when fully vaccinated; the Delta COVID-19 variant is associated with a 2-fold greater risk of hospitalization; an extra vaccine dose may boost COVID-19 protection in organ transplant recipients.
June 14, 2021
National Institutes of Health–sponsored research examines the underlying cause of COVID-19–induced diabetes.
These review results show tested immunotherapies had mostly temporar were mixed on the use of immunotherapy to treat narcolepsy, with benefits typically being temporaryy benefits and that because a majority of studies that investigated their use were small, larger studies are needed.
Real-world data confirmed the clinical effectiveness of Celltrion Healthcare’s rituximab biosimilar (Truxima, CT-P10) in patients with diffuse large B-cell lymphoma (DLBCL).
Out-of-pocket (OOP) spending for patients with heart failure with reduced ejection fraction rose in the event of a worsening heart failure event across the 4 phases of Medicare Part D coverage.